(31) discovered a potent compound, CYD-6-17, that significantly inhibited the proliferation of drug-resistant RCC cells with different genetic profiles in vitro and exhibited in vivo efficacy in three established drug-resistant RCC cell lines: HK-2 KD and 786-O KD, which are resistant to mTOR and tyrosine kinase inhibitors, and Sor001, derived from sorafenib-resistant mRCC patients. The gene discussed is MTOR; the disease is renal cell carcinoma.